Elevation Oncology Stops Gastric Cancer Study, Slashes Staff By 70%

On Thursday, Elevation Oncology, Inc. ELEV elected to discontinue the development of EO-3021, a Claudin 18.2 antibody-drug conjugate (ADC). The company was developing a treatment for advanced, unresectable or metastatic gastric and gastroesophageal junction cancers. The decision came due to disappointing data from the dose escalation and expansion stages of Elevation Oncology's Phase 1 trial. Treatment with EO-3021 as monotherapy demonstrated an objective response rate of 22.2% (1 confirmed complete respons ...